共 50 条
- [31] First-in-human, phase I dose-escalation study of investigational drug MLN9708, a second-generation proteasome inhibitor, in advanced nonhematologic malignancies.JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)Rodler, E. T.Infante, J. R.Siu, L. L.Smith, D. C.Sullivan, D.Vlahovic, G.Gomez-Navarro, J.Liu, G.Blakemore, S.Thompson, A.
- [32] First in Human Phase I Imaging Study With 89Zr-IAB22M2C Anti CD8 Minibody in Patients with Solid TumorsJOURNAL OF NUCLEAR MEDICINE, 2018, 59Pandit-Taskar, NeetaPostow, MichealO'Donoghue, JosephHarding, JamesZiolkowska, MarthaLyashchenko, SergeLewis, JasonWu, AnnaLe, WilliamGudas, JeanKorn, RonaldTorgov, MichaelWolchok, JeddWeber, Wolfgang
- [33] A FIRST-IN-HUMAN PHASE I STUDY OF M6223 (TIGIT INHIBITOR) AS MONOTHERAPY OR IN COMBINATION WITH BINTRAFUSP ALFA IN PATIENTS WITH METASTATIC OR LOCALLY ADVANCED SOLID UNRESECTABLE TUMORSJOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 : A561 - A561Watson, GeoffreyMcKean, MeredithTolcher, AnthonyVictor, AnjaZhang, SenPierre, VadrynRichter, EmiliaNaing, AungNaing, Aung
- [34] First-in-Human Phase I Dose Escalation Study of a Second-Generation Non-Ansamycin HSP90 Inhibitor, AT13387, in Patients with Advanced Solid TumorsCLINICAL CANCER RESEARCH, 2015, 21 (01) : 87 - 97Shapiro, Geoffrey I.Kwak, EuniceDezube, Bruce J.Yule, MurrayAyrton, JohnLyons, JohnMahadevan, Daruka
- [35] First-in-human Phase I study of M4112, the first dual inhibitor of indoleamine 2,3-dioxygenase-1 and tryptophan 2,3-dioxygenase 2, in patients with advanced solid malignanciesCANCER RESEARCH, 2019, 79 (13)Papadopoulos, KyriakosEder, PaulPiha-Paul, Sarina A.Gimmi, ClaudeHussey, ElizabethZhang, SenLi, LuHabermehl, ChristinaNaing, Aung
- [36] Pharmacokinetic and pharmacodynamic analysis of M7824, a dual anti-PD-L1 and TGFβ TRAP molecule, in the first-in-human phase I dose escalation studyCANCER RESEARCH, 2017, 77Cao, LiangKang, ZhigangLi, LinghuiStrauss, JuliusDussault, IsabelleGulley, James
- [37] A first-in-human phase I study of the ATM inhibitor M4076 in patients with advanced solid tumors (DDRiver Solid Tumors 410): Part 1A resultsCANCER RESEARCH, 2023, 83 (08)Siu, Lillian L.Yap, Timothy A.Genta, SofiaPennock, GregoryHicking, ChristineYou, XiaoliMukker, Jatinder K.Locatelli, GiuseppeTolcher, Anthony W.
- [38] First in Human, Phase I/II Trial of the Bruton's Tyrosine Kinase Inhibitor (BTKi) M7583 in Patients with B Cell Malignancies: Study Design and Initial OutcomesBLOOD, 2017, 130Jurczak, WojciechRule, SimonTownsend, WilliamTucker, DavidDyroff, MartinSarholz, BarbaraScheele, JurgenGribben, John G.Zinzani, Pier Luigi
- [39] A first-in-human phase I study of MORAb-004 (M4), a humanized monoclonal antibody recognizing endosialin (TEM-1), in patients with solid tumorsJOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)Diaz, Luis A.Azad, Nilofer SabaGounder, Mrinal M.Coughlin, Christina MarieFishel, JeanO'Shannessy, DanielGrasso, LuigiWustner, JasonAluri, JagadeeshParno, JeffCarvajal, Richard D.
- [40] Preclinical investigations and a first-in-human phase I trial of M4112, the first dual inhibitor of indoleamine 2,3-dioxygenase 1 and tryptophan 2,3-dioxygenase 2, in patients with advanced solid tumorsJOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 (02)Naing, AungEder, Joseph P.Piha-Paul, Sarina A.Gimmi, ClaudeHussey, ElizabethZhang, SenHildebrand, VeraHosagrahara, VinayakHabermehl, ChristinaMoisan, JacquesPapadopoulos, Kyriakos P.